Пролонгированная форма такролимуса в ведении реципиентов почечного трансплантата
- Авторы: Свистунов А.А1, Фомин В.В1
-
Учреждения:
- ГБОУ ВПО «Первый МГУМ им. И.м. Сеченова» Минздрава России
- Выпуск: № 6 (2013)
- Страницы: 29-32
- Раздел: Статьи
- URL: https://journals.eco-vector.com/2075-3594/article/view/261906
- ID: 261906
Цитировать
Полный текст
![Открытый доступ](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_open.png)
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_unlock.png)
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Аннотация
Представлен опыт применения пролонгированной формы циклоспорина реципиентами почечного трансплантата. Приведены результаты клинических исследований, демонстрирующих сопоставимую эффективность и безопасность стандартной и пролонгированной форм такролимуса, назначаемых 1 раз в сутки.
Ключевые слова
Полный текст
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Об авторах
А. А Свистунов
ГБОУ ВПО «Первый МГУМ им. И.м. Сеченова» Минздрава Россиипрофессор, проректор по учебной работе, заведующий кафедрой фармакологии фармацевтического факультета Москва
В. В Фомин
ГБОУ ВПО «Первый МГУМ им. И.м. Сеченова» Минздрава России
Email: FOMIN_VIC@MAIL.RU
профессор, декан лечебного факультета, профессор кафедры внутренних профессиональных болезней и пульмонологии медико-профилактического факультета Москва
Список литературы
- Gentile S., Beauger D., Speyer E. et al. Factors associated with health-related quality of life in renal transplant recipients: results of a national survey in France// Health Qual Life Outcomes. - Vol. 30;11(1). - P. 88. [Epub ahead of print]
- Maglakelidze N., Pantsulaia T., Tchokhonelidze I. et al. Assessment of health-related quality of life in renal transplant recipients and dialysis patients // Transplant Proc. - 2011. - Vol. 43(1). - P. 376-379.
- Chisholm-Burns M.A., Erickson S.R., Spivey C.A. et al. Health-related quality of life and employment among renal transplant recipients // Clin Transplant. - 2012. - Vol. 26(3). - P. 411-417.
- Totti V, Zancanaro M., Trerotola M. et al. Quality of life and energy expenditure in transplant recipient football players // Transplant Proc. - 2013. - Vol. 45(7). - P. 2758-2760.
- Calia R., Lai C., Aceto P. et al. Effects of switching from twice-daily to once-daily tacrolimus formulation on quality of life, anxiety, and transplant benefit perception after kidney transplantation // Transplant Proc. - 2011. - Vol. 43(4). - P. 1020-1023.
- Kuypers D.R., Peeters P.C., Sennesael.JJ. et al. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring/ADMIRAD Study Team// Transplantation. -2013. - Vol. 95(2). - P. 333-340.
- Krämer B.K., Charpentier B., Bäckman L. et al. Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study / Tacrolimus Prolonged Release Renal Study Group // Am J Transplant. - 2010. - Vol. 10(12). - P. 2632-2643.
- Iaria G., Sforza D., Angelico R. et al. Switch from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in kidney transplantation // Transplant Proc. - 2011. - Vol. 43(4). - P. 1028-1029.
- Nakamura Y., Hama K., Katayama H. et al. Safety and efficacy of conversion from twice-daily tacrolimus (prograf) to once-daily prolonged-release tacrolimus (graceptor) in stable kidney transplant recipients // Transplant Proc. - 2012. - Vol. 44(1). - P. 124-127.
- Midtvedt K., Jenssen T., Hartmann A. et al. No change in insulin sensitivity in renal transplant recipients converted from standard to once-daily prolonged release tacrolimus //Nephrol Dial Transplant. - 2011. - Vol. 26(11). -P. 3767-3772.
- Weiler N., Thrun I., Eberlin M. et al. Tacrolimus effects and side effects after liver transplantation: is there a difference between immediate and extended release?
- Kurnatowska I., Krawczyk J., Oleksik T. et al. Tacrolimus dose and blood concentration variability in kidney transplant recipients undergoing conversion from twice daily to once daily modified release tacrolimus // Transplant Proc. - 2011. - Vol. 43(8). - P. 2954-2956.
- Bunnapradist S., Ciechanowski K., West-Thielke P. et al. Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial/ MELT investigators// Am J Transplant. -2013. - Vol. 13(3). - P. 760-769.
- Gaber A.O., Alloway R.R., Bodziak K. et al. Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients// Transplantation. - 2013. -Vol. 96(2). - P. 191-197.
- Fanous H., Zheng R., Campbell C. et al. A comparison of the extended-release and standard-release formulations of tacrolimus in de novo kidney transplant recipients: a 12-month outcome study // Clin Kidney J. - 2013. - Vol. 6(1). -P. 45-49.
- Kitada H., Okabe Y., Nishiki T. et al. One-year follow-up of treatment with once-daily tacrolimus in de novo renal transplant // Exp Clin Transplant. - 2012. - Vol. 10(6). - P. 561-567.
- Slatinska J., Rohal T., Wohlfahrtova M. et al. Long-term follow-up of stable kidney transplant recipients after conversion from tacrolimus twice daily immediate release to tacrolimus once-daily prolonged release: a large singlecenter experience // Transplant Proc. - 2013. - Vol. 45(4). - P. 1491-1496.
- Uchida J., Kuwabara N., Machida Y. et al. Conversion of stable kidney transplant recipients from a twice-daily prograf to a once-daily tacrolimus formulation: a short-term study on its effects on glucose metabolism // Transplant Proc. - 2012. - Vol. 44(1). - P. 128-133.
- Wu S.W., Tsai H.C., Tsai P.Y. et al. Conversion to prolonged release tacrolimus formulation in stable kidney transplant recipients // Swiss Med Wkly. - 2013. - Vol. 143. - P. w13850.
- Guirado L., Cantarell C., Franco A. et al. Efficacy and safety of conversion from twice-daily to once-daily tacrolimus in a large cohort of stable kidney transplant recipients / GREAT Study Group // Am J Transplant. - 2011. -Vol. 11(9). - P. 1965-1971.
- Tsuchiya T., Ishida H., Tanabe T. et al. Comparison of pharmacokinetics and pathology for low-dose tacrolimus once-daily and twice-daily in living kidney transplantation: prospective trial in once-daily versus twice-daily tacrolimus // Transplantation. - 2013. - Vol. 96(2). - P. 198-204.
- Kolonko A., Chudek J., Wiecek A. Improved kidney graft function after conversion from twice daily tacrolimus to a once daily prolonged-release formulation // Transplant Proc. - 2011. - Vol. 43(8). - P. 2950-2953.
- Carcas-Sansuán A.J., Espinosa-Román L., Almeida-Paulo G.N. et al. Conversion from Prograf to Advagraf in stable paediatric renal transplant patients and 1-year follow-up // Pediatr Nephrol. - 2013 Aug 2. [Epub ahead of print].
- Albano L., Banas B., Klempnauer J.L. et al. On behalf of the Optimising immuno Suppression After Kidney transplantation with ADVAGRAF (OSAKA) study group. OSAKA Trial: A Randomized, Controlled Trial Comparing Tacrolimus QD and BD in Kidney Transplantation // Transplantation. - 2013 Aug 26. [Epub ahead of print].
- Sessa A., Esposito A., Iavicoli G. et al. Cardiovascular risk factors in renal transplant patients after switch from standard tacrolimus to prolonged-release tacrolimus// Transplant Proc. - 2012. - Vol. 44(7). - P. 1901-1906.
- Ho E.T., Wong G., Craig J.C. et al. Once-daily extended-release versus twice-daily standard-release tacrolimus in kidney transplant recipients: a systematic review // Transplantation. - 2013. - Vol. 95(9). - P. 1120-1128.
Дополнительные файлы
![](/img/style/loading.gif)